Search research articles
Contact Us
Filters
Showing results (51-60 of 111) with videos related to
Page
of 12
Sort By:
Oncotarget
|
February 22, 2024
Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas
Thomas M Cardillo, Maria B Zalath, Roberto Arrojo, et al.
Haematologica
|
August 24, 2014
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma
Thomas E Witzig, Michael B Tomblyn, Jamal G Misleh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2003
Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy
Edmund A Rossi, Robert M Sharkey, William McBride, et al.
Radiology
|
January 30, 2008
Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model
Robert M Sharkey, Habibe Karacay, Shankar Vallabhajosula, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 8, 2003
Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients
Jeffry A Siegel, Dion Yeldell, David M Goldenberg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 19, 2009
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma
Robert M Sharkey, Habibe Karacay, Christine R Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 27, 2004
Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy
Thomas M Cardillo, Habibe Karacay, David M Goldenberg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 6, 2005
Clinical-scale radiolabeling of a humanized anticarcinoembryonic antigen monoclonal antibody, hMN-14, with residualizing 131I for use in radioimmunotherapy
Serengulam V Govindan, Gary L Griffiths, Rhona Stein, et al.
Molecular Cancer Therapeutics
|
October 29, 2017
Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody-Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)
Robert M Sharkey, Serengulam V Govindan, Thomas M Cardillo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 13, 2010
A novel facile method of labeling octreotide with (18)F-fluorine
Peter Laverman, William J McBride, Robert M Sharkey, et al.
Page
of 12
Search research articles
Search
Showing results (51-60 of 111) with videos related to
Sort By:
Page
of 12
Oncotarget
|
February 22, 2024
Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas
Thomas M Cardillo, Maria B Zalath, Roberto Arrojo, et al.
Haematologica
|
August 24, 2014
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma
Thomas E Witzig, Michael B Tomblyn, Jamal G Misleh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2003
Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy
Edmund A Rossi, Robert M Sharkey, William McBride, et al.
Radiology
|
January 30, 2008
Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model
Robert M Sharkey, Habibe Karacay, Shankar Vallabhajosula, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 8, 2003
Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients
Jeffry A Siegel, Dion Yeldell, David M Goldenberg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 19, 2009
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma
Robert M Sharkey, Habibe Karacay, Christine R Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 27, 2004
Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy
Thomas M Cardillo, Habibe Karacay, David M Goldenberg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 6, 2005
Clinical-scale radiolabeling of a humanized anticarcinoembryonic antigen monoclonal antibody, hMN-14, with residualizing 131I for use in radioimmunotherapy
Serengulam V Govindan, Gary L Griffiths, Rhona Stein, et al.
Molecular Cancer Therapeutics
|
October 29, 2017
Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody-Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)
Robert M Sharkey, Serengulam V Govindan, Thomas M Cardillo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 13, 2010
A novel facile method of labeling octreotide with (18)F-fluorine
Peter Laverman, William J McBride, Robert M Sharkey, et al.
Page
of 12